U.S. drug pricing rules could impact launches in Europe

ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email

Novartis CEO Vas Narasimhan tells CNBC the company doesn’t expect near‑term effects from President Trump’s “most favoured nation” drug‑pricing order. But he warns the policy could slow new drug launches in Europe long-term unless governments value medicines more in line with the U.S.

02:31

Wed, Feb 4 202610:03 AM EST